Capital Adept
  • Politics
  • Investing
  • Stocks
  • Business
  • Politics
  • Investing
  • Stocks
  • Business

Capital Adept

Business

UnitedHealthcare sued by shareholders over reaction to CEO’s killing

by admin May 9, 2025
May 9, 2025
UnitedHealthcare sued by shareholders over reaction to CEO’s killing

A group of investors sued UnitedHealthcare Group on Wednesday, accusing the company of misleading them after the killing of its CEO, Brian Thompson.

The class action lawsuit — filed in the Southern District of New York — accuses the health insurance company of not initially adjusting their 2025 net earning outlook to factor in how Thompson’s killing would affect their operations.

On Dec. 3 — a day before Thompson was fatally shot — the company issued guidance that included net earnings of $28.15 to $28.65 per share and adjusted net earnings of $29.50 to $30.00 per share, the suit notes. And on January 16, the company announced that it was sticking with its old forecast.

The investors described this as “materially false and misleading,” pointing to the immense public scrutiny the company and the broader health insurance industry experienced in the wake of Thompson’s killing.

The group, which is seeking unspecified damages, argued that the public backlash prevented the company from pursuing ‘the aggressive, anti-consumer tactics that it would need to achieve’ its earnings goals.

‘As such, the Company was deliberately reckless in doubling down on its previously issued guidance,’ the suit reads.

The company eventually revised its 2025 outlook on April 17, citing a needed shift in corporate strategy — a move that caused its stock to drop more than 22% that day.

‘The company denies any allegations of wrongdoing and intends to defend the matter vigorously,’ a UnitedHealthcare spokesperson said in a statement.

Thompson’s fatal shooting on the streets of New York City in broad daylight sent shockwaves across the nation.

Luigi Mangione, the 27-year-old man accused of the killing, has pleaded not guilty to federal and state charges against him. The legal defense fund for Mangione surpassed the $1 million mark in donations on Tuesday.

This post appeared first on NBC NEWS

previous post
Fed Watch: Key Bullish Patterns in the S&P 500, Utilities, and Crypto
next post
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

Related Posts

Fanatics will host a skills challenge between fans...

May 22, 2025

Fintech company Chime files for Nasdaq IPO

May 14, 2025

Howard Schultz says he ‘did a cartwheel’ when...

June 13, 2025

IBM pledges $150 billion to boost U.S. tech...

April 29, 2025

Netflix stock is trading at all-time high levels...

May 3, 2025

Temu slashes U.S. ad spending, plummets in App...

April 17, 2025

How Fanatics is teaching business acumen to pro...

June 25, 2025

Harvard’s battle with the Trump administration is creating...

April 19, 2025

AMC bets on premium screens as Hollywood slate...

April 1, 2025

Musk says time commitment to DOGE will ‘drop...

April 24, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Copper Price Update: Q1 2025 in Review

      April 14, 2025
    • 2

      The Best Five Sectors, #10

      March 14, 2025
    • 3

      DP Trading Room: Market Sell-Off

      March 14, 2025
    • 4

      5 Strong Stocks Defying the Bearish Market!

      March 14, 2025
    • 5

      Sector Rotation Warning: More Downside Ahead for US Markets?

      March 14, 2025
    • 6

      Transform Your Investing Strategy: Uncover the 3 Game-Changing Rules

      March 14, 2025
    • 7

      Did Friday’s Reversal Mark A Major Bottom?

      March 14, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 capitaladept.com | All Rights Reserved